NASDAQ: KEQU

KEWAUNEE SCIENTIFIC CORP /DE/

CIK 0000055529 · SIC 3821 · Lab Apparatus & Furniture

Small Revenue $282M Assets $176M as of Sep 23, 2026

Kewaunee Scientific Corporation (the "Company") was founded in 1906, incorporated in Michigan in 1941, became publicly-held in 1968, and was reincorporated in Delaware in 1970. Our principal business is the design, manufacture, and installation of laboratory, healthcare, and technical furniture and… About this business →

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (SRBK 10-K) is open in full — no account needed.

10-Q Filed Sep 11, 2026 · Period ending Jul 31, 2026

Summary not yet generated.

8-K Filed Sep 9, 2026 · Period ending Sep 9, 2026

Summary not yet generated.

Partner

Trade KEQU commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Aug 27, 2026 · Period ending Aug 26, 2026

Summary not yet generated.

8-K Filed Aug 26, 2026 · Period ending Aug 26, 2026

Summary not yet generated.

8-K Filed Aug 25, 2026 · Period ending Aug 25, 2026

Summary not yet generated.

10-K Filed Jun 26, 2026 · Period ending Apr 30, 2026

KEQU: revenue $282.0M, net income $9.6M. KEQU sales +17% on Nu Aire, but backlog falls 23% and net earnings drop 16%

5 material changes detected. Sign up free to read the summary.

8-K Filed Jun 23, 2026 · Period ending Jun 23, 2026

Summary not yet generated.

8-K Filed Jun 10, 2026 · Period ending Jun 10, 2026

Summary not yet generated.

10-Q Filed Mar 13, 2026 · Period ending Jan 31, 2026

Summary not yet generated.

8-K Filed Mar 11, 2026 · Period ending Mar 11, 2026

Summary not yet generated.

10-Q Filed Dec 12, 2025 · Period ending Oct 31, 2025

Summary not yet generated.

10-K Filed Jul 2, 2025 · Period ending Apr 30, 2025

Summary not yet generated.

Latest financial statements

From 10-Q filed Sep 11, 2026 (period ending Jul 31, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations (Unaudited)

($ and shares in thousands, except per share amounts)

Description Three months ended July 31, 2026 Three months ended July 31, 2025
Net sales 66,320 71,104
Cost of products sold 46,681 50,174
Gross profit 19,639 20,930
Operating expenses 16,481 16,120
Operating profit 3,158 4,810
Other income, net 28 168
Interest expense (626) (1,058)
Profit before income taxes 2,560 3,920
Income tax expense 717 761
Net earnings 1,843 3,159
Less: Net earnings attributable to the non-controlling interest 137 66
Net earnings attributable to Kewaunee Scientific Corporation 1,706 3,093
Net earnings per share attributable to Kewaunee Scientific Corporation stockholders
Basic 0.59 1.08
Diluted 0.58 1.04
Weighted average number of common shares outstanding
Basic 2,880 2,851
Diluted 2,921 2,963

Condensed Consolidated Balance Sheets

($ and shares in thousands, except per share amounts)

Description July 31, 2026 (Unaudited) April 30, 2026
Assets
Current Assets:
Cash and cash equivalents 8,246 9,950
Restricted cash 2,015 1,667
Receivables, less allowance; $667; $633, on each respective date 58,197 58,738
Inventories 29,786 30,533
Prepaid expenses and other current assets 5,707 4,509
Total Current Assets 103,951 105,397
Property, plant and equipment, at cost 75,146 74,375
Accumulated depreciation (53,214) (52,008)
Property, plant and equipment, net 21,932 22,367
Right of use assets 10,277 10,791
Deferred income taxes 3,642 3,829
Intangible assets, net 15,910 16,294
Goodwill 12,487 12,487
Other assets 7,601 7,146
Total Assets 175,800 178,311
Liabilities and Stockholders' Equity
Current Liabilities:
Short-term borrowings 627 74
Current portion of financing liability 887 867
Current portion of term loans 4,893 4,893
Current portion of financing lease liabilities 71 70
Current portion of operating lease liabilities 4,100 3,775
Accounts payable 21,557 22,455
Employee compensation and amounts withheld 6,677 8,822
Deferred revenue 5,185 4,152
Other accrued expenses 3,238 3,243
Total Current Liabilities 47,235 48,351
Long-term portion of financing liability 25,533 25,765
Long-term portion of term loans 13,581 14,804
Long-term portion of financing lease liabilities 263 282
Long-term portion of operating lease liabilities 5,517 6,287
Accrued pension and deferred compensation costs 5,165 4,807
Deferred income taxes 995 913
Other non-current liabilities 291 290
Total Liabilities 98,580 101,499
Commitments and Contingencies
Stockholders' Equity:
Common stock, $2.50 par value, Authorized 5,000 shares; Issued – 3,012 shares; 2,969 shares; Outstanding – 2,895 shares; 2,866 shares, on each respective date 7,531 7,423
Additional paid-in-capital 6,026 7,019
Retained earnings 70,243 68,537
Accumulated other comprehensive loss (4,619) (4,614)
Common stock in treasury, at cost, 117 shares; 103 shares, on each respective date (4,176) (3,647)
Total Kewaunee Scientific Corporation Stockholders' Equity 75,005 74,718
Non-controlling interest 2,215 2,094
Total Stockholders' Equity 77,220 76,812
Total Liabilities and Stockholders' Equity 175,800 178,311

Condensed Consolidated Statements of Cash Flows (Unaudited)

($ in thousands)

Description Three months ended July 31, 2026 Three months ended July 31, 2025
Cash flows from operating activities:
Net earnings 1,843 3,159
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization 1,591 1,549
Provision for credit losses 67 19
Stock-based compensation expense 1,899 521
Cash-settled restricted stock units (1,753) —
Deferred income taxes 269 (154)
Accrued payment in kind ("PIK") interest — 445
Amortization of deferred financing costs 56 94
Change in assets and liabilities:
Receivables 474 5,468
Inventories 747 (2,074)
Accounts payable and other accrued expenses (3,047) (1,525)
Deferred revenue 1,032 (1,090)
Other, net (1,202) (621)
Net cash provided by operating activities 1,976 5,791
Cash flows from investing activities:
Capital expenditures (772) (771)
Net cash used in investing activities (772) (771)
Cash flows from financing activities:
Repayments on term loans (1,250) (750)
Proceeds from short-term borrowings 17,797 1,377
Repayments on short-term borrowings (17,244) (1,869)
Payments on sale-leaseback financing transaction (226) (207)
Payments on long-term lease obligations (17) (14)
Taxes paid related to net share settlement of equity awards (1,030) —
Purchase of treasury stock (529) —
Net cash used in financing activities (2,499) (1,463)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (61) (280)
(Decrease) increase in cash, cash equivalents and restricted cash (1,356) 3,277
Cash, cash equivalents and restricted cash, beginning of period 11,617 17,164
Cash, cash equivalents and restricted cash, end of period 10,261 20,441

Amounts as printed on the EDGAR/iXBRL face — ($ and shares in thousands, except per share amounts); ($ in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

About KEWAUNEE SCIENTIFIC CORP /DE/

Source: Item 1 (Business) from the 10-K filed June 26, 2026. Description as filed by the company with the SEC.

Item 1. Business

GENERAL

Kewaunee Scientific Corporation (the "Company") was founded in 1906, incorporated in Michigan in 1941, became publicly-held in 1968, and was reincorporated in Delaware in 1970. Our principal business is the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Our products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. Our acquisition of Nu Aire, Inc., ("Nu Aire"), completed in November 2024, complements the Company's portfolio through Nu Aire's biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products. Nu Aire is renowned for its manufacturing of biological safety cabinets, airflow products, CO2 incubators, ultralow freezers, animal handling equipment, pharmacy compounding isolators, and related parts and accessories. Their products serve a diverse range of industries, including life sciences, healthcare, pharmacy, education, food and beverage, and industrial sectors.

The acquisition of Nu Aire presented a unique opportunity for the Company to combine its robust capabilities with a recognized market leader whose product portfolio and well-developed channel strategy complement the Company's offerings. The acquisition also expanded the Company's capabilities, allowing the combined organization to better meet the diverse needs of end-users in laboratory furnishings. Additionally, Nu Aire has established distribution partners in regions where the Company did not previously have a presence, accelerating the Company's vision of becoming the market leader in the design and manufacturing of laboratory furniture and technical products essential for outfitting laboratories.

Read full description ↓

See Note 4, Nu Aire Acquisition, of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for information concerning the nature and terms of the acquisition.

Our international subsidiaries, as identified in Note 1, Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K, provide products and services, including facility design, detailed engineering construction, and project management from the planning stage through testing and commissioning of laboratories.

Our products are sold primarily through purchase orders and contracts submitted by customers directly or through our dealers, our subsidiaries in Singapore and India, and a national distributor. Products are sold principally to pharmaceutical, biotechnology, industrial, chemical and commercial research laboratories, educational institutions, healthcare institutions, governmental entities, and manufacturing facilities. We consider the markets in which we compete to be highly competitive, with a significant amount of the business involving competitive public bidding.

It is common in the laboratory and healthcare furniture industries for customer orders to require delivery at extended future dates, as products are frequently installed in buildings yet to be constructed. Changes or delays in building construction may cause delays in delivery of the orders and our recognition of the sale. Since prices are normally quoted on a firm basis in the industry, we bear the burden of possible increases in labor and material costs between quotation of an order and delivery of the product. The impact of such possible increases is considered when determining the sales price. The primary raw materials and products manufactured by others and used by us in our products are cold-rolled carbon and stainless steel, hardwood lumber and plywood, paint, chemicals, resins, hardware, plumbing and electrical fittings. Such materials and products are purchased from multiple suppliers and are typically readily available.

Our need for working capital and our credit practices are comparable to those of other companies manufacturing, selling and installing similar products in similar markets. Since our products are used in building construction projects, in many cases payments for our products are received over longer periods of time than payments for many other types of manufactured products, thus requiring increased working capital. In addition, payment terms associated with certain projects provide for a retention amount until final completion of the project, thus also increasing required working capital. On average, payments for our products are received during the quarter following shipment, with the exception of the retention amounts which are collected at the final completion of the project.

We hold various patents and patent rights, but do not consider that our success or growth is dependent upon our patents or patent rights. Our business is not dependent upon licenses, franchises, concessions, trademarks, royalty agreements, or labor contracts.

Our business is not generally cyclical, although domestic sales are sometimes lower during our third quarter because of slower construction activity in certain areas of the country during the winter months. Sales for two of the Company's domestic dealers and our national stocking distributor represented, in the aggregate, approximately 34% and 41% of the Company's sales in fiscal years 2026 and 2025, respectively. Loss of all or part of our sales to a large customer would have a material effect on our financial operations.

Our order backlog at April 30, 2026 was $165.9 million, as compared to $214.6 million at April 30, 2025. Based on scheduled shipment dates and past experience, we estimate that not less than 90% of our order backlog at April 30, 2026 will be shipped during fiscal year 2027. However, it may be expected that delays in shipments will occur because of customer rescheduling or delay in completion of projects which involve the installation of our products.

SEGMENT INFORMATION

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources and in assessing performance. The Company's Chief Executive Officer ("CEO") is the Company's CODM. In accordance with ASC 280, Segment Reporting, the Company determined that the CODM assesses the Company's operations and manages its businesses in two segments: Lab Products Group ("LPG") and International. The Lab Products Group segment consists of the Company's operations based out of Statesville, North Carolina and Kewaunee's subsidiary, Nu Aire, Inc., based out of Plymouth, Minnesota. The International segment consists of the foreign subsidiaries identified in Note 1, Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.

We measure our segment profitability based on earnings before income taxes. Some Corporate expenses, such as those related to executive management, finance, etc., are allocated to the segments. Any non-allocated Corporate costs are shown separately in our segment reporting as presented in Note 14, Segment Information, of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.

See Note 14, Segment Information, of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for further segment financial data.

COMPETITION

We consider the industries in which we participate to be highly competitive and believe that the principal deciding factors are price, product performance, and customer service. A significant portion of our business is based upon competitive public bidding.

RESEARCH AND EXPERIMENTATION EXPENDITURES

The amount spent and expensed by us during the fiscal year ended April 30, 2026 on research and experimentation expenditures activities related to new or redesigned products was $898,000. The amount spent for similar purposes in the fiscal year ended April 30, 2025 was $919,000.

ENVIRONMENTAL COMPLIANCE

In the last two fiscal years, compliance with federal, state, or local provisions enacted or adopted regulating the discharge of materials into the environment has had no material effect on us and such regulation is not expected to have a material effect on our earnings or competitive position in the future.

CULTURE AND WORKFORCE

We are a company of passionate, talented, and motivated people. We embrace collaboration and creativity, and we encourage the iteration of ideas to address complex challenges within our industry and society.

At April 30, 2026, the Company had 755 domestic employees and 476 international employees. Our people are critical for our continued success, so we work hard to create an environment where employees can have fulfilling careers, and be happy, healthy, and productive. We offer competitive benefits, an award-winning Well Living program, and other resources to take care of the diverse needs of our employees and their families. These include opportunities for career growth and development, resources to support their financial health, and access to excellent healthcare choices and resources, including a recently expanded onsite wellness center and separate gym facility at Kewaunee's Statesville, NC headquarters, as well as regular access to onsite specialists. Our competitive compensation programs help us attract and retain top candidates. We will continue to invest in recruiting talented people to technical and non-technical roles, and celebrate their contributions with comprehensive rewards and recognition.

The Company believes that open and honest communication among team members, managers, and leaders helps create a collaborative work environment where everyone can contribute, grow, and succeed. Team members are encouraged to come to their managers with questions, feedback, or concerns, and the Company conducts surveys that gauge employee engagement.

When necessary, we contract with businesses around the world to provide specialized services where we do not have appropriate in-house expertise or resources. We also contract with temporary staffing agencies when we need to cover short-term leaves, when we have spikes in business needs, or when we need to quickly incubate special projects. We choose our partners and staffing agencies carefully and continually make improvements to promote a respectful and positive working environment for everyone - employees, vendors, and temporary staff alike.

OTHER INFORMATION

We file annual, quarterly, and current reports and other information with the Securities and Exchange Commission (the "SEC"). The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

Our Internet address is www.kewaunee.com. We make available, free of charge through this website, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The reference to our website does not constitute incorporation by reference of any information contained at that site.

EXECUTIVE OFFICERS OF THE REGISTRANT

Included in Part III, Item 10(b), Directors, Executive Officers and Corporate Governance, of this Annual Report on Form 10-K.